Abstract:To investigate response and survival of radiotherapy (RT) for hepatocellular carcinoma with tumor thrombosis in main portal vein or vena cava, and to analyze prognostic factors. From January 2010 to December 2016, a total of 61 cases of hepatocellular carcinoma with pathological or clinical diagnosis of hepatocellular carcinoma with tumor thrombosis in main portal vein or vena cava were enrolled this study. Main portal vein tumor thrombosis (PVTT) was defined as tumor thrombi was located in main trunk or first branches of portal vein. Fifty-five patients were with PVTT and 4 patients were with venous vein tumor thrombosis alone, respectively. In addition, another 2 patients were with both vein thromboses. All patients had a liver function of Child-Pugh A before radiotherapy. Eighty-five percent of patients (52/61) had a history of hepatitis B, 2% (2/61) had hepatitis C, and 12% (7/61) had no history of hepatitis. Eighty-four percent of patients (51/61) had previously received transcatheter arterial chemoembolization (TACE). Eight patients were treated with concurrent RT and sorafenib. Tumor response was evaluated in one to three months after completion of RT. Survival and prognostic factors were analyzed by Kaplan-Meier method and Cox regression model. The factors included gender, age, history of hepatitis, AFP level before radiotherapy, number of intrahepatic lesions, maximum tumor diameter (MTD), combined TACE, radiotherapy dose were included in analysis of prognosis. All patients were treated with intensity modulated radiotherapy by conventional fraction of 2Gy/f. The median dose was 50Gy (28-66Gy). Response rate (RR, complete response + partial response) was 55.7% when considering all lesions of whole body. In field of RT, RR of the primary tumor was 77.1% and RR of the tumor thrombosis was 83.7%. The 2-year overall survival was 29.9% and median survival time (MST) was 13.6 months. Median time to progression (TTP) was 4.7 months. The 2-year progression free survival of tumor thrombosis was 88.6%. Multivariate analysis showed that the MTD>10cm was an independent poor prognostic factor of TTP (HR, 1.961, 95%CI, 1.034-3.717). TTP in patients with MTD≤10cm and MTD>10cm were 5.0 months and 3.3 months (p=0.026), respectively. However, for MST, combination of TACE (both before or after RT) was an independent favor prognostic factor (HR, 0.184, 95%CI, 0.06-0.565). MST of combination therapy was 15 months, and MST of patients receiving radiotherapy alone was 4 months (p<0.001). Of all patients, grade III or higher liver function damage was 1.6%, and no lethal radiation-induced liver disease occurred. Grade III or higher hematological toxicity was 11.5%. The tumor thrombosis is more sensitive to radiation therapy than the primary tumor. Radiotherapy improves survival by the perfect control of tumor thrombosis. Progression of outside field of RT is primary failure mode for patients with main PVTT. Combination of radiotherapy and TACE is benefit to survivals.

A comparison of treatment combinations with and without radiotherapy for the hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus

A Comparison of Treatment Combinations with and Without Radiotherapy for Hepatocellular Carcinoma with Portal Vein And/or Inferior Vena Cava Tumor Thrombus.

Influence of Tumor Thrombus Location on the Outcome of External-beam Radiation Therapy in Advanced Hepatocellular Carcinoma with Macrovascular Invasion

Prognostic Factors for Patients with Hepatocellular Carcinoma with Macroscopic Portal Vein or Inferior Vena Cava Tumor Thrombi Receiving External‐beam Radiation Therapy

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Radiotherapy with Targeted Therapy or Immune Checkpoint Inhibitors for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombi

Efficacy And Prognosis Of Radiotherapy For Hepatocellular Carcinoma With Tumor Thrombosis In Main Portal Vein Or/And Vena Cava

[Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors].

A Comparison of Chemoembolization Combination with and Without Radiotherapy for Unresectable Hepatocellular Carcinoma

[Comparison of the Results and Therapies for Hepatocellular Carcinoma with Tumor Thrombosis in Portal Vein].

Comparison Between Radioimmunotherapy and External Beam Radiation Therapy for Patients with Hepatocellular Carcinoma

The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus.

Radomized comparative study of hepatocellular carcinoma with extensive portal vein tumor thrombus treated by TACE combined with or without endovascular implantation of iodine-125 seeds strand

Effectiveness Of Stereotactic Body Radiotherapy For Hepatocellular Carcinoma With Portal Vein And/Or Inferior Vena Cava Tumor Thrombosis

Endovascular brachytherapy vs.sequential three-dimensional conformal radiotherapy for the treatment of main portal vein tumor thrombus: a comparative study

Determining the Role of External Beam Radiotherapy in Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Analysis of 84 Patients

Portal Vein Irradiation Stent Plus Chemoembolization Versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study.

Impact of treatment strategies on patients with hepatocellular carcinoma of less than 10 cm but with portal vein tumor thrombus

External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial

Efficacy of Different Treatment Strategies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus